Theravance Biopharma, Inc. Operating Expenses
Theravance Biopharma, Inc. (TBPH) reported Operating Expenses of $29.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Theravance Biopharma, Inc. operating expenses for the quarter ending 2026-06-30 was $29.01M, a 0.30% increase year-over-year.
- Theravance Biopharma, Inc. operating expenses for the quarter ending 2026-03-31 was $27.18M, a 8.85% decline year-over-year.
- Theravance Biopharma, Inc. operating expenses for the quarter ending 2025-12-31 was $25.88M, a 7.42% decline year-over-year.
- Theravance Biopharma, Inc. operating expenses for the quarter ending 2025-09-30 was $26.45M, a 4.55% decline year-over-year.
- Theravance Biopharma, Inc. operating expenses for fiscal 2025 was $111.07M, a 0.24% decline from fiscal 2024.
- Theravance Biopharma, Inc. operating expenses for fiscal 2024 was $111.33M, a 1.88% decline from fiscal 2023.
- Theravance Biopharma, Inc. operating expenses for fiscal 2023 was $113.46M, a 20.83% decline from fiscal 2022.
- Theravance Biopharma, Inc. operating expenses for fiscal 2022 was $143.30M, a 54.23% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $29.01M 10-Q · filed 2026-08-11 | $56.19M 10-Q · filed 2026-08-11 | $82.07M derived: sum of 3 quarters · filed 2026-08-11 | $108.51M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $27.18M 10-Q · filed 2026-05-07 | $53.06M derived: sum of 2 quarters · filed 2026-05-07 | $79.51M derived: sum of 3 quarters · filed 2026-05-07 | $108.43M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $25.88M 10-K · filed 2026-03-23 | $52.32M derived: sum of 2 quarters · filed 2026-03-23 | $81.24M derived: sum of 3 quarters · filed 2026-08-11 | $111.07M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $26.45M 10-K · filed 2026-03-23 | $55.37M derived: sum of 2 quarters · filed 2026-08-11 | $85.19M 10-Q · filed 2025-11-12 | $113.14M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $28.92M 10-Q · filed 2026-08-11 | $58.74M 10-Q · filed 2026-08-11 | $86.70M derived: sum of 3 quarters · filed 2026-08-11 | $114.40M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $29.82M 10-Q · filed 2026-05-07 | $57.78M derived: sum of 2 quarters · filed 2026-05-07 | $85.48M derived: sum of 3 quarters · filed 2026-05-07 | $115.44M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $27.95M 10-K · filed 2026-03-23 | $55.66M derived: sum of 2 quarters · filed 2026-03-23 | $85.62M derived: sum of 3 quarters · filed 2026-03-23 | $111.33M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $27.70M 10-K · filed 2026-03-23 | $57.67M derived: sum of 2 quarters · filed 2026-03-23 | $83.38M 10-Q · filed 2025-11-12 | $107.18M derived: sum of 4 quarters · filed 2026-03-23 | |||
| 2024-06-30 | $29.96M 10-K · filed 2026-03-23 | $55.67M 10-Q · filed 2025-08-13 | $79.48M derived: sum of 3 quarters · filed 2026-03-23 | $103.93M derived: sum of 4 quarters · filed 2026-03-23 | |||
| 2024-03-31 | $25.71M 10-K · filed 2026-03-23 | $49.52M derived: sum of 2 quarters · filed 2026-03-23 | $73.97M derived: sum of 3 quarters · filed 2026-03-23 | $103.84M derived: sum of 4 quarters · filed 2026-03-23 | |||
| 2023-12-31 | $23.80M 10-K · filed 2025-03-07 | $48.26M derived: sum of 2 quarters · filed 2025-03-07 | $78.13M derived: sum of 3 quarters · filed 2025-03-07 | $113.46M 10-K · filed 2025-03-07 | |||
| 2023-09-30 | $24.45M 10-K · filed 2025-03-07 | $54.33M derived: sum of 2 quarters · filed 2025-03-07 | $89.65M 10-Q · filed 2024-11-14 | $121.73M derived: sum of 4 quarters · filed 2025-03-07 | |||
| 2023-06-30 | $29.87M 10-K · filed 2025-03-07 | $65.20M 10-Q · filed 2024-08-08 | $97.28M derived: sum of 3 quarters · filed 2025-03-07 | $118.88M derived: sum of 4 quarters · filed 2025-03-07 | |||
| 2023-03-31 | $35.33M 10-K · filed 2025-03-07 | $67.41M derived: sum of 2 quarters · filed 2025-03-07 | $89.00M derived: sum of 3 quarters · filed 2025-03-07 | $126.93M derived: sum of 4 quarters · filed 2025-03-07 | |||
| 2022-12-31 | $32.08M 10-K · filed 2024-03-01 | $53.68M derived: sum of 2 quarters · filed 2024-03-01 | $91.61M derived: sum of 3 quarters · filed 2024-03-01 | $143.30M 10-K · filed 2024-03-01 | |||
| 2022-09-30 | $21.59M 10-K · filed 2024-03-01 | $26.65M 10-Q · filed 2022-11-09 | $59.52M derived: sum of 2 quarters · filed 2024-03-01 | $111.22M 10-Q · filed 2023-11-09 | $182.34M derived: sum of 4 quarters · filed 2024-03-01 | ||
| 2022-06-30 | $37.93M 10-K · filed 2024-03-01 | $84.57M 10-Q · filed 2023-08-09 | $89.63M 10-Q · filed 2022-08-08 | $160.74M derived: sum of 3 quarters · filed 2024-03-01 | $227.55M derived: sum of 4 quarters · filed 2024-03-01 | ||
| 2022-03-31 | $51.70M 10-K · filed 2024-03-01 | $122.81M derived: sum of 2 quarters · filed 2024-03-01 | $189.62M derived: sum of 3 quarters · filed 2024-03-01 | $266.64M derived: sum of 4 quarters · filed 2024-03-01 | |||
| 2021-12-31 | $71.11M 10-K · filed 2023-03-01 | $137.92M derived: sum of 2 quarters · filed 2023-03-01 | $214.95M derived: sum of 3 quarters · filed 2023-03-01 | $313.10M 10-K · filed 2023-03-01 | |||
| 2021-09-30 | $66.81M 10-K · filed 2023-03-01 | $143.83M derived: sum of 2 quarters · filed 2023-03-01 | $241.98M 10-Q · filed 2022-11-09 | $337.20M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | $77.02M 10-K · filed 2023-03-01 | $175.17M 10-Q · filed 2022-08-08 | $270.39M derived: sum of 3 quarters · filed 2023-03-01 | $365.26M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | $98.15M 10-K · filed 2023-03-01 | $193.37M derived: sum of 2 quarters · filed 2023-03-01 | $288.24M derived: sum of 3 quarters · filed 2023-03-01 | $375.43M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $95.22M 10-K · filed 2022-02-28 | $190.09M derived: sum of 2 quarters · filed 2022-02-28 | $277.28M derived: sum of 3 quarters · filed 2022-02-28 | $369.48M 10-K · filed 2023-03-01 | $369.61M 10-K · filed 2021-02-26 | ||
| 2020-09-30 | $94.87M 10-K · filed 2022-02-28 | $182.06M derived: sum of 2 quarters · filed 2022-02-28 | $274.39M 10-Q · filed 2021-11-08 | $374.46M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $87.18M 10-K · filed 2022-02-28 | $179.52M 10-Q · filed 2021-08-05 | $279.59M derived: sum of 3 quarters · filed 2022-02-28 | $357.22M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | $92.34M 10-K · filed 2022-02-28 | $192.41M derived: sum of 2 quarters · filed 2022-02-28 | $270.04M derived: sum of 3 quarters · filed 2022-02-28 | $338.66M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $100.07M 10-K · filed 2021-02-26 | $177.70M derived: sum of 2 quarters · filed 2021-02-26 | $246.32M derived: sum of 3 quarters · filed 2021-02-26 | $325.33M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $77.63M 10-K · filed 2021-02-26 | $146.25M derived: sum of 2 quarters · filed 2021-02-26 | $225.26M 10-Q · filed 2020-11-09 | $303.62M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-06-30 | $68.63M 10-K · filed 2021-02-26 | $147.63M 10-Q · filed 2020-08-10 | $225.99M derived: sum of 3 quarters · filed 2021-02-26 | $301.28M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-03-31 | $79.00M 10-K · filed 2021-02-26 | $157.36M derived: sum of 2 quarters · filed 2021-02-26 | $232.65M derived: sum of 3 quarters · filed 2021-02-26 | $304.83M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2018-12-31 | $78.36M 10-K · filed 2020-02-27 | $153.65M derived: sum of 2 quarters · filed 2020-02-27 | $225.83M derived: sum of 3 quarters · filed 2020-02-27 | $299.12M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $75.29M 10-K · filed 2020-02-27 | $147.47M derived: sum of 2 quarters · filed 2020-02-27 | $220.76M 10-Q · filed 2019-11-08 | $304.45M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-06-30 | $72.18M 10-K · filed 2020-02-27 | $145.47M 10-Q · filed 2019-08-05 | $229.17M derived: sum of 3 quarters · filed 2020-02-27 | $290.44M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-03-31 | $73.30M 10-K · filed 2020-02-27 | $156.99M derived: sum of 2 quarters · filed 2020-02-27 | $218.26M derived: sum of 3 quarters · filed 2020-02-27 | $286.89M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2017-12-31 | $83.69M 10-K · filed 2019-02-28 | $144.96M derived: sum of 2 quarters · filed 2019-02-28 | $213.59M derived: sum of 3 quarters · filed 2019-02-28 | $275.51M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $61.27M 10-K · filed 2019-02-28 | $129.90M derived: sum of 2 quarters · filed 2019-02-28 | $191.82M 10-Q · filed 2018-11-08 | $255.34M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-06-30 | $68.63M 10-K · filed 2019-02-28 | $130.55M 10-Q · filed 2018-08-02 | $194.07M derived: sum of 3 quarters · filed 2019-02-28 | $246.64M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-03-31 | $61.92M 10-K · filed 2019-02-28 | $125.44M derived: sum of 2 quarters · filed 2019-02-28 | $178.01M derived: sum of 3 quarters · filed 2019-02-28 | $230.98M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2016-12-31 | $63.53M 10-K · filed 2018-02-28 | $116.09M derived: sum of 2 quarters · filed 2018-02-28 | $169.06M derived: sum of 3 quarters · filed 2018-02-28 | $229.12M 10-K · filed 2019-02-28 | |||
| 2016-09-30 | $52.57M 10-K · filed 2018-02-28 | $105.54M derived: sum of 2 quarters · filed 2018-02-28 | $165.59M 10-Q · filed 2017-11-08 | $225.26M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2016-06-30 | $52.97M 10-K · filed 2018-02-28 | $113.02M 10-Q · filed 2017-08-09 | $172.69M derived: sum of 3 quarters · filed 2018-02-28 | $226.48M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2016-03-31 | $60.05M 10-K · filed 2018-02-28 | $119.72M derived: sum of 2 quarters · filed 2018-02-28 | $173.51M derived: sum of 3 quarters · filed 2018-02-28 | $225.94M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2015-12-31 | $59.67M 10-K · filed 2017-03-01 | $113.46M derived: sum of 2 quarters · filed 2017-03-01 | $165.89M derived: sum of 3 quarters · filed 2017-03-01 | $224.03M 10-K · filed 2018-02-28 | |||
| 2015-09-30 | $53.79M 10-K · filed 2017-03-01 | $106.22M derived: sum of 2 quarters · filed 2017-03-01 | $164.36M 10-Q · filed 2016-11-09 | $231.54M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-06-30 | $52.43M 10-K · filed 2017-03-01 | $110.56M 10-Q · filed 2016-08-09 | $177.75M derived: sum of 3 quarters · filed 2017-03-01 | $234.15M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-03-31 | $58.14M 10-K · filed 2017-03-01 | $125.32M derived: sum of 2 quarters · filed 2017-03-01 | $181.72M derived: sum of 3 quarters · filed 2017-03-01 | $241.40M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | $67.19M 10-K · filed 2016-03-11 | $123.58M derived: sum of 2 quarters · filed 2016-03-11 | $183.26M derived: sum of 3 quarters · filed 2016-03-11 | $244.23M 10-K · filed 2017-03-01 | |||
| 2014-09-30 | $56.40M 10-K · filed 2016-03-11 | $116.08M derived: sum of 2 quarters · filed 2016-03-11 | $177.04M 10-Q · filed 2015-11-12 | $221.30M derived: sum of 4 quarters · filed 2016-03-11 | |||
| 2014-06-30 | $59.68M 10-K · filed 2016-03-11 | $120.64M 10-Q · filed 2015-08-13 | $164.90M derived: sum of 3 quarters · filed 2016-03-11 | $206.00M derived: sum of 4 quarters · filed 2016-03-11 | |||
| 2014-03-31 | $60.96M 10-K · filed 2016-03-11 | $105.22M derived: sum of 2 quarters · filed 2016-03-11 | $146.32M derived: sum of 3 quarters · filed 2016-03-11 | $185.28M derived: sum of 4 quarters · filed 2016-03-11 | |||
| 2013-12-31 | $44.26M 10-K · filed 2015-03-13 | $85.36M derived: sum of 2 quarters · filed 2015-03-13 | $124.31M derived: sum of 3 quarters · filed 2015-03-13 | $156.51M 10-K · filed 2016-03-11 | |||
| 2013-09-30 | $41.10M 10-K · filed 2015-03-13 | $80.06M derived: sum of 2 quarters · filed 2015-03-13 | $112.25M 10-Q · filed 2014-11-12 | ||||
| 2013-06-30 | $38.96M 10-K · filed 2015-03-13 | $71.15M 10-Q · filed 2014-08-14 | |||||
| 2013-03-31 | $32.20M 10-K · filed 2015-03-13 | ||||||
| 2012-12-31 | $139.72M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |